Veracyte is adding urologic cancer tests to its genomics testing portfolio with the acquisition of Decipher Biosciences.
Veracyte acquired Decipher for $600m in cash, the companies announced on 15 March
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?